title: Alterations in semen parameters in men with epilepsy treated with valproate or carbamazepine monotherapy.
abstract: Men with epilepsy are known to have reduced fertility. Whether this is drug-induced or a result of the epilepsy itself is still under debate. Few studies have been carried out on semen from men with epilepsy. The aim of the present study was first to investigate possible drug-specific effects of long-term treatment with either valproate or carbamazepine on semen quality and testicular size, and secondly to see whether the results in epilepsy patients differed from healthy fertile males. Men with epilepsy, 20-40 years old, having used either valproate (n = 16) or carbamazepine (n = 20) for >2 years, were included. The semen data of healthy fertile men without epilepsy in the same age group (n = 90) were used as controls. The semen was examined according to WHO (1999). No significant differences in semen quality were seen between men receiving either valproate or carbamazepine. However, semen from the valproate-treated, as opposed to the carbamazepine-treated, differed from controls with regard to tail abnormalities. Absolute testicular size was not significantly different between the two treatment groups. However, after correcting for changes in body mass index (BMI), the testicular size/BMI ratio was lower in the valproate-treated patients. The valproate-treated patients gained significantly more weight than the carbamazepine-treated patients after start of current medication. No differences between the patient groups were found in terms of libido/potency or number of pregnancies fathered. When comparing all epilepsy patients with healthy fertile males, there was a significant reduction in the percentage of rapidly progressive motile sperms in the semen from epileptic patients. The semen from men with epilepsy also showed significant differences from the controls regarding neck and head abnormalities of the spermatozoa.
authors.affiliation: Department of Neurology, Rikshospitalet, University of Oslo, Norway. line.sveberg.roste@rikshospitalet.no
authors.forename: L S
authors.initials: LS
authors.lastname: Røste
authors.forename: E
authors.initials: E
authors.lastname: Taubøll
authors.forename: T B
authors.initials: TB
authors.lastname: Haugen
authors.forename: T
authors.initials: T
authors.lastname: Bjørnenak
authors.forename: E R
authors.initials: ER
authors.lastname: Saetre
authors.forename: L
authors.initials: L
authors.lastname: Gjerstad
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D002220:Carbamazepine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D004827:Epilepsy / Q000188:drug therapy*; D006801:Humans; D008297:Male; D012661:Semen / Q000166:cytology / Q000187:drug effects* / Q000502:physiology; D013076:Sperm Count / Q000706:statistics & numerical data; D013094:Spermatozoa / Q000187:drug effects* / Q000473:pathology / Q000502:physiology; D018709:Statistics, Nonparametric; D014635:Valproic Acid / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D002220:Carbamazepine; D014635:Valproic Acid